The results in Fig. 5A, C show that intravenous injection of CCL22 into KYSE410 and KYSE510 xenografts increased the tumor size (Fig. 5A) and enhanced the activation of AKT (Fig. 5B) and the expression of Ki67, CD31, and LYVE-1 (Fig. 5C), as evaluated by quantitative ELISAs. This evidence concerns the gene LYVE1 and neoplasm.